Abstract
Advancement in the understanding of biologic mechanisms of low-grade glioma pathophysiology has allowed the modern era of patient-specific genetic profiling, molecular biology, and neuroimaging to design new methods of surgery, radiation, and chemotherapy in hopes of preventing malignant transformation and improving outcomes. Recent innovations in the understanding of MGMT promoter methylation, IDH1 and IDH2 mutations, temozolomide chemotherapy, vascular monoclonal antibody treatment, use of radiation therapy, choice of antiepileptic drugs, surgical resection, and neuroimaging of lowgrade gliomas are reviewed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 369-380 |
| Number of pages | 12 |
| Journal | Current Treatment Options in Neurology |
| Volume | 14 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 1 2012 |
| Externally published | Yes |
Keywords
- 1p/19q deletion
- Chemotherapy
- Clinical trials
- IDH1 mutation
- IDH2 mutation
- Low-grade glioma
- PCV
- Prognostic factors
- Progression-free survival
- Surgery
- Survival
- TMZ
- Treatment
- Vaccination
ASJC Scopus subject areas
- Clinical Neurology
Fingerprint Dive into the research topics of 'Recent innovations in the management of low-grade gliomas'. Together they form a unique fingerprint.
Cite this
Hafeez, S., & Cavaliere, R. (2012). Recent innovations in the management of low-grade gliomas. Current Treatment Options in Neurology, 14(4), 369-380. https://doi.org/10.1007/s11940-012-0185-6